Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors
about
G-protein coupled receptor expression patterns delineate medulloblastoma subgroupsPheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatmentExpressions of Somatostatin Receptor Subtypes (SSTR-1, 2, 3, 4 and 5) in Neuroblastic Tumors; Special Reference to Clinicopathological Correlations with International Neuroblastoma Pathology Classification and Outcomes.Peptide Receptor Radionuclide Therapy (PRRT) in a Patient Affected by Metastatic Breast Cancer with Neuroendocrine Differentiation.The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursRadical resection and enucleation in Chinese adolescents with pancreatic tumors: A 15-year case series.Yttrium-labelled peptides for therapy of NET.Radionuclide therapy of adrenal tumors.Ten challenges in the management of neuroblastoma.Retinoids in pediatric onco-hematology: the model of acute promyelocytic leukemia and neuroblastoma.Nanovectorized radiotherapy: a new strategy to induce anti-tumor immunity.Improved synthesis and biological evaluation of chelator-modified α-MSH analogs prepared by copper-free click chemistry.Correlation of Somatostatin Receptor-2 Expression with Gallium-68-DOTA-TATE Uptake in Neuroblastoma Xenograft Models.Safety and accuracy of 68Ga-DOTATOC PET/CT in children and young adults with solid tumors.Immunohistochemical evaluation of molecular radiotherapy target expression in neuroblastoma tissue.
P2860
Q28302285-1813EB95-26B3-4579-8F13-50530902F14BQ34410500-E971F1FB-3E38-45B6-926C-CCCA1D232770Q35288725-D1F280FE-E0BF-4B87-AE83-D4694B477637Q36457850-CEF94AF4-E71B-4B65-82F4-572B8E1E3522Q36755905-D8E502E7-DD39-4260-A401-90D72BD151DDQ37727296-A3EB36B7-FAC8-4C83-80FE-280AAB9796E3Q37990401-BBA6A01C-D2E6-48DD-AE1E-A8C0B8389902Q38020428-24664319-165D-4BDF-BCCA-FF8F65EA2F30Q38029366-A568CED1-2235-4B93-B5A5-D5D2D2F46F56Q38039970-74275B95-01FB-43D7-8AD9-1453DC69CE34Q38054112-CD571E47-6708-4B67-8469-CA0568631406Q38382330-D4E9D6D8-C000-49B7-84EA-A9B87FA4482BQ43376054-624A8EC0-CC98-436D-8393-D713C71DDB80Q47155891-344A8554-95F8-43B9-A550-85CEF02FF45EQ47771714-4F2A8D1C-9767-4E16-932C-C13F436B0AD8
P2860
Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase I trial of 90Y-DOTATOC t ...... express somatostatin receptors
@en
Phase I trial of 90Y-DOTATOC t ...... xpress somatostatin receptors.
@nl
type
label
Phase I trial of 90Y-DOTATOC t ...... express somatostatin receptors
@en
Phase I trial of 90Y-DOTATOC t ...... xpress somatostatin receptors.
@nl
prefLabel
Phase I trial of 90Y-DOTATOC t ...... express somatostatin receptors
@en
Phase I trial of 90Y-DOTATOC t ...... xpress somatostatin receptors.
@nl
P2093
P2860
P50
P1476
Phase I trial of 90Y-DOTATOC t ...... express somatostatin receptors
@en
P2093
Geetika Khanna
John Babich
Mark Madsen
Mary Connolly
Stacy Michael
P2860
P304
P356
10.2967/JNUMED.110.075226
P407
P577
2010-09-16T00:00:00Z